First Real Life Evidence of New Direct-acting Antivirals (DAA) in Co-infected HIV HCV Patients: Better than Ever Reply

被引：0

作者：

Shafran, Stephen D. ^{[1
]}

机构：

[1] Univ Alberta, Dept Med, Edmonton, AB T6G 2G3, Canada

来源：

CLINICAL INFECTIOUS DISEASES | 2016年 / 62卷 / 07期

关键词：

HEPATITIS-C; VIROLOGICAL RESPONSE; TELAPREVIR; REGIMENS; THERAPY; COHORT;

D O I：

10.1093/cid/civ1217

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：949 / +

页数：2

共 8 条

[1] Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 US Veterans [J].

Backus, L. I. ;

Belperio, P. S. ;

Shahoumian, T. A. ;

Loomis, T. P. ;

Mole, L. A. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (05) :559-573

[2] Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection [J].

Martel-Laferriere, V. ;

Brinkley, S. ;

Bichoupan, K. ;

Posner, S. ;

Stivala, A. ;

Perumalswami, P. ;

Schiano, T. D. ;

Sulkowski, M. ;

Dieterich, D. T. ;

Branch, A. D. .

HIV MEDICINE, 2014, 15 (02) :108-115

[3] First Real Life Evidence of New Direct-acting Antivirals (DAA) in Co-infected HIV HCV Patients: Better than Ever [J].

Menard, Amelie ;

Colson, Philippe ;

Catherine, Dhiver ;

Isabelle, Ravaux ;

Christelle, Tomei ;

Meddeb, Line ;

Ben Ali, Souad ;

Solas, Caroline ;

Stein, Andreas .

CLINICAL INFECTIOUS DISEASES, 2016, 62 (07)

[4] Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients [J].

O'Neil, Conar R. ;

Pang, Jack X. Q. ;

Lee, Samuel S. ;

Swain, Mark G. ;

Burak, Kelly W. ;

Klein, Patricia ;

Myers, Robert P. ;

Kapler, Jeff ;

Gill, Michael J. ;

Labrie, Martin ;

Coffin, Carla S. .

CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2015, 26 (06) :293-296

[5] Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake [J].

Schaerer, V. ;

Haubitz, S. ;

Kovari, H. ;

Ledergerber, B. ;

Ambrosioni, J. ;

Cavassini, M. ;

Stoeckle, M. ;

Schmid, P. ;

Decosterd, L. ;

Aouri, M. ;

Boeni, J. ;

Guenthard, H. F. ;

Furrer, H. ;

Metzner, K. J. ;

Fehr, J. ;

Rauch, A. .

HIV MEDICINE, 2015, 16 (10) :599-607

[6] Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir [J].

Sterling, R. K. ;

Kuo, A. ;

Rustgi, V. K. ;

Sulkowski, M. S. ;

Stewart, T. G. ;

Fenkel, J. M. ;

El-Genaidi, H. ;

Mah'moud, M. A. ;

Abraham, G. M. ;

Stewart, P. W. ;

Akushevich, L. ;

Nelson, D. R. ;

Fried, M. W. ;

Di Bisceglie, A. M. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (07) :671-685

[7] Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir [J].

Vo, Kevin P. ;

Vutien, Philip ;

Akiyama, Matthew J. ;

Vu, Vinh D. ;

Ha, Nghiem B. ;

Piotrowski, Joy I. ;

Wantuck, James ;

Roytman, Marina M. ;

Tsai, Naoky ;

Cheung, Ramsey ;

Li, Jiayi ;

Nguyen, Mindie H. .

DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (04) :1045-1051

[8] Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV) [J].

Walker, David R. ;

Pedrosa, Marcos C. ;

Manthena, Shivaji R. ;

Patel, Nikil ;

Marx, Steven E. .

ADVANCES IN THERAPY, 2015, 32 (11) :1117-1127

← 1 →